Blood cancer patients with COVID-19 fare better with convalescent plasma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
APEIRON Biologics APN01 selected for large-scale US trial in COVID-19
DGAP-News: APEIRON Biologics AG / Key word(s): Study
19.05.2021 / 09:00
APEIRON Biologics APN01 selected for large-scale US trial
in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
Vienna, Austria, 19 May 2021: APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery rou
APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
VIENNA, AUSTRIA / ACCESSWIRE / May 19, 2021 / APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery routes.
by Bill Snyder
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.
Comprised of the hormones renin, angiotensin and aldosterone, RAAS is essential for the regulation of blood pressure and fluid balance. SARS-CoV-2, the virus that causes COVID-19, can disrupt this system, resulting in life-threatening complications, including pulmonary edema, thromboembolic complications and severe cardiac injury.
Sean Collins, MD, MSc, professor of Emergency Medicine at Vanderbilt University Medical Center, who has deep expertise in emergency care and RAAS, will lead the trial, which will test whether drugs targeting RAAS can prevent the vascular, fibrotic and inflammatory consequences of severe COVID-19 disease.
NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms
Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.
The National Institutes of Health will fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial.